Advance your academic career, collaborate globally, and expand your network— join now !

EVANGELOS OIKONOMOU

Share Link

Share

Information

Prof. Evangelos Oikonomou is a clinical fellow in cardiovascular medicine, a post-doctoral research fellow in the Cardiovascular Data Science (CarDS) lab, and a member of the ABIM Physician-Scientist Research Pathway at Yale. He graduated as valedictorian of his class from the University of Athens Medical School in Greece, before pursuing a Ph.D. degree at the University of Oxford, where he was recognized with the Radcliffe Department of Medicine Graduate Prize for his scientific work. In 2019, he joined the Physician-Scientist Training Program at the Yale School of Medicine, and he has since completed his internal medicine residency and his core clinical fellowship in cardiology. His work focuses on the intersection of applied computer vision and statistical machine learning, with a specific focus on developing tools for the improved phenotyping of cardiovascular disease using scalable approaches that can be deployed at minimal cost using existing care pathways.

Research Keywords & Expertise

Cardiovascular
Heart Failure
myocardial fibrosis
Cardiovascular diesase
myocardial infarction,

Short Biography

Prof. Evangelos Oikonomou is a clinical fellow in cardiovascular medicine, a post-doctoral research fellow in the Cardiovascular Data Science (CarDS) lab, and a member of the ABIM Physician-Scientist Research Pathway at Yale. He graduated as valedictorian of his class from the University of Athens Medical School in Greece, before pursuing a Ph.D. degree at the University of Oxford, where he was recognized with the Radcliffe Department of Medicine Graduate Prize for his scientific work. In 2019, he joined the Physician-Scientist Training Program at the Yale School of Medicine, and he has since completed his internal medicine residency and his core clinical fellowship in cardiology. His work focuses on the intersection of applied computer vision and statistical machine learning, with a specific focus on developing tools for the improved phenotyping of cardiovascular disease using scalable approaches that can be deployed at minimal cost using existing care pathways.